Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024.
Since the announcement 24 June 2024, the following transactions have been made:
Number of
B sharesAverage
purchase priceTransaction
value, DKKAccumulated, last announcement1,150,040 1,082,466,72224 June 202436,500987.9336,059,59025 June 202429,8351,009.1630,108,23926 June 202439,0001,016.1639,630,40427 June 202436,0001,003.3736,121,43928 June 202436,0001,006.9236,249,003Accumulated under the programme1,327,375 1,260,635,397
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 11,427,189 B shares of DKK 0.10 as treasury shares, corresponding to 0.3% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 28 June 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 10,061,625 B shares at an average share price of DKK 873.45 per B share equal to a transaction value of DKK 8,788,370,170.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific
